News
![Median Technologies Reports Full Year 2019 Financial Results](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Median Technologies Reports Full Year 2019 Financial Results
Regulatory News:
Median Technologies (Paris:ALMDT), The Imaging Phenomics Company®, reported today its full year 2019 financial results. Median Technologies’ Board of Directors approved the
![EOS imaging Announces the Rescheduling of the Publication of Its Annual Results](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
EOS imaging Announces the Rescheduling of the Publication of Its Annual Results
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
![Im Rahmen einer globalen Partnerschaft mit Nestlé Health Science initiiert VALBIOTIS die zulassungsrelevante letzte Phase der klinischen Entwicklung von TOTUM-63](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Im Rahmen einer globalen Partnerschaft mit Nestlé Health Science initiiert VALBIOTIS die zulassungsrelevante letzte Phase der klinischen Entwicklung von TOTUM-63
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL/PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
![As Part of a Global Partnership with Nestlé Health Science, VALBIOTIS Initiates the Pivotal Late Stage Development Phase of TOTUM-63, a Plant-Derived Active Substance With Clinically Demonstrated Metabolic Health Benefits in People With Prediabetes](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
As Part of a Global Partnership with Nestlé Health Science, VALBIOTIS Initiates the Pivotal Late Stage Development Phase of TOTUM-63, a Plant-Derived Active Substance With Clinically Demonstrated Metabolic Health Benefits in People With Prediabetes
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic
![Sensorion Reports Full-year 2019 Financial Results and Business Update](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Sensorion Reports Full-year 2019 Financial Results and Business Update
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage and gene therapy biotech company which specializes in the development of novel therapies to treat, prevent and
![Kerlink und ZENNER IoT Solutions stellen Deutschlands größtes LoRaWAN®-Netzwerk für Energie-, Gas- und Wasserversorgungsunternehmen bereit](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Kerlink und ZENNER IoT Solutions stellen Deutschlands größtes LoRaWAN®-Netzwerk für Energie-, Gas- und Wasserversorgungsunternehmen bereit
Kerlink (AKLK – FR0013156007), ein Anbieter von Lösungen für das Internet of Things (IoT), und ZENNER IoT Solutions GmbH, der führende deutsche LoRaWAN®-Systemintegrator und Lösungsanbieter, haben
![Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the
![Mauna Kea Technologies Receives FDA Clearance And CE Marking For Its Next-Generation Cellvizio® Platform](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Mauna Kea Technologies Receives FDA Clearance And CE Marking For Its Next-Generation Cellvizio® Platform
Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE)
![GenSight Biologics Announces Presentation of Bilateral Visual Recovery From GS010 (LUMEVOQ™) Phase III Trials at the 46th Annual Meeting of NANOS](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
GenSight Biologics Announces Presentation of Bilateral Visual Recovery From GS010 (LUMEVOQ™) Phase III Trials at the 46th Annual Meeting of NANOS
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for
![Assistance Publique – Hôpitaux de Paris (AP-HP) And Median Technologies Reach a Research Collaboration Agreement Involving The iBiopsy® Platform](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Assistance Publique – Hôpitaux de Paris (AP-HP) And Median Technologies Reach a Research Collaboration Agreement Involving The iBiopsy® Platform
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200302005737/en/
Assistance Publique–Hôpitaux de Paris (AP-HP), the
![BIOCORP: Mallya-Marketingpartnerschaft mit iSage Rx im Bereich digitale Diabeteskontrolle](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
BIOCORP: Mallya-Marketingpartnerschaft mit iSage Rx im Bereich digitale Diabeteskontrolle
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / PEA/KMU-qualifiziert), ein französisches Unternehmen mit Spezialisierung in der Entwicklung und Herstellung von Medizinprodukten und intelligenten
![BIOCORP: Marketing Partnership on Mallya with iSage Rx in the Field of Digital Diabetes](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
BIOCORP: Marketing Partnership on Mallya with iSage Rx in the Field of Digital Diabetes
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery
![Sensorion appoints gene therapy expert Dr Géraldine Honnet as Chief Medical Officer](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Sensorion appoints gene therapy expert Dr Géraldine Honnet as Chief Medical Officer
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent
![Sensorion Receives Ethics Committee Approval to Include New Military Sites in SENS-401 Phase 2 study](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Sensorion Receives Ethics Committee Approval to Include New Military Sites in SENS-401 Phase 2 study
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the
![Sensorion Announces the Full Conversion of Sofinnova Partners Convertible Bonds Into Ordinary Shares](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Sensorion Announces the Full Conversion of Sofinnova Partners Convertible Bonds Into Ordinary Shares
Regulatory News:
Sensorion (FR0012596468 – ALSEN / PEA-PME eligible) (Paris:ALSEN), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore
![Sensorion Announces the Full Conversion of Invus Convertible Bonds Into Ordinary Shares](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Sensorion Announces the Full Conversion of Invus Convertible Bonds Into Ordinary Shares
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN / PEA-PME eligible), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore
![VALBIOTIS meldet weltweite strategische Partnerschaft mit NESTLÉ HEALTH SCIENCE bei der Entwicklung und Vermarktung von TOTUM-63, ein pflanzlicher Wirkstoff mit klinisch nachgewiesenem Nutzen für die Stoffwechselgesundheit bei Prädiabetes](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
VALBIOTIS meldet weltweite strategische Partnerschaft mit NESTLÉ HEALTH SCIENCE bei der Entwicklung und Vermarktung von TOTUM-63, ein pflanzlicher Wirkstoff mit klinisch nachgewiesenem Nutzen für die Stoffwechselgesundheit bei Prädiabetes
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Prävention und Bekämpfung von
![VALBIOTIS Announces a Global Strategic Partnership With NESTLÉ HEALTH SCIENCE For the Development and Commercialization of TOTUM-63, a Plant-derived Active Substance With Clinically Demonstrated Metabolic Health Benefits on Prediabetics](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
VALBIOTIS Announces a Global Strategic Partnership With NESTLÉ HEALTH SCIENCE For the Development and Commercialization of TOTUM-63, a Plant-derived Active Substance With Clinically Demonstrated Metabolic Health Benefits on Prediabetics
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible ), a Research & Development company committed to scientific innovation for preventing and combating metabolic
![Sensorion to Attend and Present at LSX World Congress 2020](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Sensorion to Attend and Present at LSX World Congress 2020
Regulatory News:
Sensorion (FR0012596468 – ALSEN / PEA-PME eligible), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and
![Sensorion Presents New SENS-401 Preclinical Data at ARO Midwinter Meeting 2020](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Sensorion Presents New SENS-401 Preclinical Data at ARO Midwinter Meeting 2020
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent
![EOS imaging: Information Relating to the Total Number of Share Capital and Voting Rights](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
EOS imaging: Information Relating to the Total Number of Share Capital and Voting Rights
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
![Mauna Kea Technologies Receives FDA 510(k) Clearance of Cellvizio® with a Fluorescent Dye, Fluorescein, as Drug Device Combination](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Mauna Kea Technologies Receives FDA 510(k) Clearance of Cellvizio® with a Fluorescent Dye, Fluorescein, as Drug Device Combination
Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (pCLE/nCLE)
![EOS imaging Announces First Installation of EOSedge™ in North America](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
EOS imaging Announces First Installation of EOSedge™ in North America
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
![Median Technologies: Financial Communications Schedule for the First Half of 2020](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Median Technologies: Financial Communications Schedule for the First Half of 2020
Regulatory News:
Median Technologies (Paris:ALMDT), The Imaging Phenomics Company® announces the publication date for its 2019 results:
Publication
Date
2019 results
April 14
![EOS imaging Reports Its Full Year 2019 Sales](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
EOS imaging Reports Its Full Year 2019 Sales
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and